Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback